News
A new report examines why linked data is essential to advancing healthcare and improving outcomes for patients.
The HS market across the 7MM is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData.
The European Medicines Agency’s CHMP has recommended approval of Gilead Sciences’ lenacapavir, a twice-yearly injection for preventing HIV infection.
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas.
The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of VRd for multiple myeloma.
The US biopharma has planted roots in the UK’s biotech cluster as it bets on synthetic rescue to unlock new treatments for rare diseases.
GSK has secured approval in the European Union (EU) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma.
Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.
Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.
In 2025, Turbine took the first steps in opening its powerful cell simulation platform to the wider drug development ...
A successful monoclonal antibody could undergo scale-up several times across the span of its commercial life, each stage ...
The EC has approved Janssen-Cilag International’s new indication for Darzalex Faspro (daratumumab) to treat adults with SMM.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results